Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | HTR2B | P41595 | 3/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19889366 | 0.77 | HTR2C (0.57) | HTR2CHTR2AHTR2BADRB2SLC6A4 | |
| SCHEMBL28657591 | 0.77 | HTR2C (0.71) | HTR2CHTR2AHTR2BADRB2SLC6A4 | |
| SCHEMBL1305048 | 0.77 | HTR2C (0.57) | HTR2CHTR2AHTR2BADRB2SLC6A4 | |
| SCHEMBL807343 | 0.74 | HTR2C (0.74) | HTR2CHTR2AHTR2BADRB2KDM4E | |
| SCHEMBL3239993 | 0.74 | HTR2C (0.57) | HTR2CHTR2AHTR2BADRB2SLC6A4 | |
| SCHEMBL14168904 | 0.73 | HTR2C (0.49) | HTR2CHTR2AHTR2BADRB2SLC6A4 | |
| SCHEMBL29287872 | 0.73 | HTR2C (0.75) | HTR2CHTR2AHTR2BADRB2SLC6A4 | |
| SCHEMBL2910862 | 0.73 | HTR2C (0.72) | HTR2CHTR2AHTR2BADRB2KDM4E | |
| SCHEMBL14168805 | 0.71 | HTR2C (0.50) | HTR2CHTR2AHTR2BADRB2SLC6A4 | |
| SCHEMBL28594057 | 0.71 | HTR2C (0.74) | HTR2CHTR2AHTR2BADRB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699761-B1 | CB1 MODULATOR COMPOUNDS | LILLY CO ELI (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-1699761-B1 | CB1 MODULATOR COMPOUNDS | LILLY CO ELI (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088018-A1 | Cb1 antagonist compounds | CNR1, CNR2, CHRNA5 | HTR2C 271/4885HTR2A 223/4885HTR2B 125/4885 |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | CNR1, CNR2, MAG | HTR2C 299/4885HTR2A 251/4885HTR2B 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.